Related Experiment Video
Updated: Feb 16, 2026

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells
Published on: August 21, 2013
PARP inhibition causes premature loss of cohesion in cancer cells
Eva Kukolj1, Tanja Kaufmann1, Amalie E Dick2
1Max F. Perutz Laboratories, University of Vienna, Vienna Biocenter (VBC), Dr. Bohr-Gasse 9, Vienna, Austria.
Abstract:
Poly(ADP-ribose) polymerases (PARPs) regulate various aspects of cellular function including mitotic progression. Although PARP inhibitors have been undergoing various clinical trials and the PARP1/2 inhibitor olaparib was approved as monotherapy for BRCA-mutated ovarian cancer, their mode of action in killing tumour cells is not fully understood. We investigated the effect of PARP inhibition on mitosis in cancerous (cervical, ovary, breast and osteosarcoma) and non-cancerous cells by live-cell imaging. The clinically relevant inhibitor olaparib induced strong perturbations in mitosis, including problems with chromosome alignment at the metaphase plate, anaphase delay, and premature loss of cohesion (cohesion fatigue) after a prolonged metaphase arrest, resulting in sister chromatid scattering. PARP1 and PARP2 depletion suppressed the phenotype while PARP2 overexpression enhanced it, suggesting that olaparib-bound PARP1 and PARP2 rather than the lack of catalytic activity causes this phenotype. Olaparib-induced mitotic chromatid scattering was observed in various cancer cell lines with increased protein levels of PARP1 and PARP2, but not in non-cancer or cancer cell lines that expressed lower levels of PARP1 or PARP2. Interestingly, the sister chromatid scattering phenotype occurred only when olaparib was added during the S-phase preceding mitosis, suggesting that PARP1 and PARP2 entrapment at replication forks impairs sister chromatid cohesion. Clinically relevant DNA-damaging agents that impair replication progression such as topoisomerase inhibitors and cisplatin were also found to induce sister chromatid scattering and metaphase plate alignment problems, suggesting that these mitotic phenotypes are a common outcome of replication perturbation.
Insights
Poly(ADP-ribose) polymerases (PARPs) inhibition disrupts mitosis, causing sister chromatid scattering in cancer cells. This occurs when PARP inhibitors like olaparib engage PARP1/2 during S-phase, impairing replication and cohesion.
Area of Science:
- Cell Biology
- Molecular Oncology
- Cancer Therapeutics
Background:
- Poly(ADP-ribose) polymerases (PARPs) are crucial for DNA repair and mitotic progression.
- PARP inhibitors, such as olaparib, are used in cancer therapy, but their precise anti-tumor mechanisms, particularly concerning mitosis, require further elucidation.
- Understanding PARP inhibitor effects on cell division is vital for optimizing cancer treatment strategies.
Purpose of the Study:
- To investigate the impact of PARP inhibition on mitosis in various cancer and non-cancerous cell types.
- To determine the role of PARP1 and PARP2 protein levels and catalytic activity in olaparib-induced mitotic defects.
- To explore the relationship between replication stress and mitotic aberrations caused by PARP inhibition.
Main Methods:
- Live-cell imaging was employed to observe mitotic progression in cancer and non-cancer cells treated with olaparib.
- PARP1 and PARP2 gene expression levels were manipulated (depletion and overexpression) to assess their influence on observed phenotypes.
- Cells were treated with olaparib during different cell cycle phases (S-phase vs. other phases) to pinpoint the timing of critical events.
Main Results:
- Olaparib induced significant mitotic perturbations, including chromosome misalignment, anaphase delay, and sister chromatid scattering due to cohesion fatigue.
- PARP1/2 depletion reversed these defects, while PARP2 overexpression exacerbated them, indicating that olaparib-bound PARP1/2, not just catalytic inactivity, drives the phenotype.
- The sister chromatid scattering phenotype was prominent in cancer cells with high PARP1/2 levels and occurred specifically when olaparib was administered during S-phase, suggesting replication fork trapping.
- Replication-perturbing agents like topoisomerase inhibitors and cisplatin mimicked these mitotic issues, highlighting a common pathway.
Conclusions:
- PARP inhibition by olaparib causes mitotic errors, specifically sister chromatid scattering, by trapping PARP1/2 at replication forks during S-phase, thereby compromising sister chromatid cohesion.
- The observed mitotic defects are dependent on the levels of PARP1 and PARP2 and are linked to replication stress, suggesting a broader implication for DNA-damaging chemotherapies.
- These findings provide critical insights into the mode of action of PARP inhibitors and their impact on cancer cell division.
Related Concept Videos
Negative Regulator Molecules
DNA Damage can Stall the Cell Cycle
DNA Damage Can Stall the Cell Cycle
Restarting Stalled Replication Forks
Abnormal Proliferation
Replicative Cell Senescence

